Reference: Therapeutic Potential Cannabidiol CBD, Cannabidiol in Medicine A Review of its Therapeutic Potential in CNS Disorders
Caterina Scuderi, Daniele De Filippis, Teresa Iuvone, Angelo Blasio, Antonio Steardo and Giuseppe Esposito
Cannabidiol (CBD) is the main non-psychotropic component of the glandular hairs of Cannabis sativa and belongs to the so-called ‘cannabinoids’ (CBs). This term refers to a heterogeneous family of molecules usually exhibiting pharmacological properties by interacting with specific receptors. So far, two membrane receptors for CBs, both coupled to G protein and named CB1 and CB2, have been identified. While CB1 receptors are mainly expressed in the central and the peripheral nervous systems, CB2 receptors have been reported to be more abundantly detected in cells of the immune system (for review see Pertwee, 2006). Moreover, two orphan G protein-coupled receptors, GPR119 and GPR55, possibly activated by multiple different cannabinoid ligands (Brown, 2007), have been recently proposed as novel cannabinoid receptors. CBs can be separated into three different groups: endogenous (endocannabinoids), synthetic and phytocannabinoids. The latter group includes terpenophenolic substances extracted from Cannabis sativa, such as Δ9-tetrahydrocannabinol (Δ9-THC) and CBD.
Cannabinoid pharmacology is a field rapidly expanding and the therapeutic properties of cannabinoid receptor agonists include analgesia, muscle relaxation, immunosuppressant, antiinflammatory and antiallergic effects, improvement of mood, stimulation of appetite, antiemesis, lowering of intraocular pressure, bronchodilatation, neuroprotection and antineoplastic effects (Pertwee, 2005). Despite the emerging evidence regarding therapeutic activities of CBs, their effective introduction in clinical use is still controversial and strongly limited by the unavoidable psychotropic effects exhibited by many of them. In this context, much attention has been focused on CBD that constitutes up to 40% of the Cannabis extract, and represents one of the most promising candidates for clinical utilization due to its remarkable lack of any cognitive and psychoactive actions. Finally, CBD is regarded as an interesting putative lead compound to develop cannabinomimetic drugs, because of its excellent tolerability in humans
Therapeutic Potential Cannabidiol CBD